Caricamento...
Effects of secukinumab on metabolic and liver parameters in plaque psoriasis patients
BACKGROUND: Psoriasis is associated with metabolic, liver and cardiovascular comorbidity. Secukinumab, a fully human monoclonal antibody that selectively neutralizes interleukin‐17A, has shown significant and sustained efficacy in the treatment of moderate to severe psoriasis. OBJECTIVES: This was a...
Salvato in:
| Pubblicato in: | J Eur Acad Dermatol Venereol |
|---|---|
| Autori principali: | , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
John Wiley and Sons Inc.
2019
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7065121/ https://ncbi.nlm.nih.gov/pubmed/31599476 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jdv.16004 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|